Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$23.15K$23.15Kderivedno prior Q4 2014 on file Net Income-$351.32K-$351.32KderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$15,469N/M Operating Incomederived-$349,268— Operating Cash Flowderived-$13,166N/M Margins · derivedGross margin-66.8%
Operating margin-1508.6%
Net margin-1517.4%
ended Dec 31, 2015 · filed Jul 22, 2016 · 204 d after period end